, Tracking Stock Market Picks
Enter Symbol:
Idenix Pharmaceuticals, Inc. (IDIX) [hlAlert]

up 606.05 %

Idenix Pharmaceuticals, Inc. (IDIX) rated Buy with price target $7 by UBS

Posted on: Friday,  May 3, 2013  10:25 AM ET by UBS

UBS rated Buy Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX) on 05/03/2013, when the stock price was $3.47. Since
then, Idenix Pharmaceuticals, Inc. has gained 606.05% as of 08/05/2014's recent price of $24.50.
If you would have followed this UBS's recommendation on IDIX, you would have gained 606.05% of your investment in 459 days.

Idenix Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases. Idenix's current focus is on the treatment of infections caused by hepatitis B virus, hepatitis C virus and human immunodeficiency virus.

UBS is the leading global wealth manager, a top tier investment banking and securities firm, and one of the largest global asset managers. In Switzerland, UBS is the market leader in retail and commercial banking. With headquarters in Zurich and Basel, Switzerland, UBS operates in over 50 countries and from all major international centers. UBS employs more than 80,000 people.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/3/2013 10:25 AM Buy
3.47 7.00
as of 12/13/2013
1 Week down  -10.54 %
1 Month down  -4.54 %
3 Months down  -19.52 %
1 YTD up  27.08 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy